By Editorial TeamA startup’s clinical advisory board is too often seen as marketing window dressing, just a list of impressive names to look legitimate. But for AI health companies trying to get through the maze of regulatory approval and clinical adoption, the board’s makeup and actual involvement can be the deciding factor, tying directly to faster FDA clearances and solid peer-reviewed papers. This is a look at why a well-built clinical advisory network is a strategic necessity and how the top-tier AI companies use these relationships to de-risk their path to market and win commercially.
Beyond the Rolodex: Clinical Advisory Boards as Strategic Assets
For VCs doing pre-investment due diligence, looking at the clinical advisory board has to go way past a quick scan of CVs. When these boards are built and engaged correctly, they are the critical link between new AI tech and the hard realities of medical practice, regulators, and evidence generation. They aren’t figureheads. They’re conduits for real-world clinical feedback, regulatory foresight, and academic weight. The real value of a good board is its ability to spot and fix problems in product development, trial design, and regulatory strategy before they happen, saving huge amounts of time and money when bringing a novel SaMD to market. The FDA 510(k) clearance process, which is the most common path for these AI health products, requires you to clearly show substantial equivalence to a device that’s already on the market. For genuinely new AI, you need the De Novo Classification pathway, which is often a much heavier lift for validation. In either case, having active clinical advisors who can give you a nuanced understanding of clinical workflows, data integrity, and patient safety can dramatically simplify your submissions, help you get ahead of FDA questions, and make sure your AI tool is both useful to doctors and compliant with regulations. This kind of proactive work, especially with advisors who have sat on FDA advisory panels themselves, can easily shave months off a clearance timeline.
Tempus AI and Cleerly: Benchmarking Clinical Governance for Regulatory Velocity
To see the real-world impact of strong clinical advisory setups, let’s look at two leaders in AI health: Tempus AI and Cleerly. Both companies are in heavily regulated and clinically sensitive fields, and their playbooks for clinical governance offer good lessons for any due diligence analyst. Tempus AI which is a precision medicine platform, has built an incredible clinical advisory network that’s woven directly into its oncology validation work. Their strategy is all about breadth and depth, pulling in a diverse group of oncologists, geneticists, pathologists, and computational biologists. The sheer size and academic horsepower of their advisory board (tons of MDs and PhDs from top institutions) is directly connected to their long list of publications. This network is how they get their hands on the large, high-quality clinical datasets you need to train and validate AI models, and it also provides the brainpower to turn complex genomic and clinical data into something a doctor can actually use for treatment decisions. It’s a symbiotic deal: Tempus gets validation from the network, and the advisors get access to advanced AI tools and data for their own research, which often results in joint peer-reviewed publications. Tempus AI went public on the Nasdaq on June 14, 2024, under the ticker “TEM”. The company keeps expanding its regulatory wins, getting 510(k) clearance for Tempus ECG-PH (pulmonary hypertension) in August 2026, its third FDA-cleared cardiovascular device. Tempus also got breakthrough status for an ECG device to spot patients at high risk of AFib and FDA approval for xT Tumor Only. In July 2026, Tempus agreed to acquire cancer-testing company Personalis. Tempus AI clinical advisory board composition and publications Cleerly, which focuses on cardiac imaging AI, shows the same dedication to clinical rigor but with a much more focused strategy. Cleerly is still a private company and has raised $578 million over five funding rounds, including a $106 million Series C extension in December 2024. Cleerly leans heavily on cardiologists to steer its imaging clinical trials and product development. Their board is full of interventional cardiologists, radiologists, and experts in cardiovascular disease prevention. That kind of deep specialization means their AI algorithms for quantifying coronary plaque and assessing cardiac risk are built with a genuine understanding of clinical workflow, diagnostic accuracy demands, and patient management protocols. You can see the board is active by the number of peer-reviewed publications its members have authored, often showing how Cleerly’s AI is both useful and accurate in a clinical setting. Cleerly received FDA Breakthrough Device Designation for its Coronary Artery Disease (CAD) Staging System in March 2024, and its Cleerly ISCHEMIA and Cleerly LABS v2.0 products also have FDA 510(k) clearances. In July 2026, Cleerly Plaque received 510(k) clearance, with the FDA’s review including its Predetermined Change Control Plan (PCCP). The American College of Cardiology continues to feature research supported by Cleerly’s technology, with the company presenting new AI-QCT research at ACC.26 in March 2026. Cleerly clinical trial publications and advisory board affiliations So you have two models here. Tempus goes wide with a big, multi-disciplinary network for the complexity of oncology, while Cleerly goes deep with focused expertise in cardiology. But the common thread is that both companies prioritize having advisors who are active researchers with strong publication records, which is a huge green flag for anyone looking at regulatory and commercial viability.
The Due Diligence Checklist: Identifying Active Researchers with Regulatory Acumen
For investors, the takeaway is clear: find companies with clinical advisory boards that are obviously active and strategically aligned. Here’s a checklist for judging board quality during due diligence:
- Size and Composition: Don’t just be impressed by a long list of MDs and PhDs. Are their specialties actually relevant to the product? Is there any observable correlation between the size of a board and how fast similar products got FDA clearance?
- Publication History: Dig into their publication history. How many papers have they authored that are directly about the company’s tech or its clinical space? Active researchers generate the evidence you need for regulators and payers.
- Regulatory Experience: Have any of them actually been on an FDA advisory panel or run large-scale trials that led to a clearance? That kind of experience is gold because they know what the FDA is going to ask before they ask it.
- Engagement Model: Find out how they’re actually engaged. Is it a quarterly call or are they deep in the weeds of product development, clinical trial design, and regulatory strategy? Look for their fingerprints on white papers, study protocols, or product feedback. Passive advisors are dead weight.
- Network Access: Does the board open doors? They should be providing intros to key opinion leaders, clinical sites for pilots, and patient cohorts for data validation. This can be a massive accelerator for R&D.
- GMLP and QMS Integration: Check if they have input on the company’s GMLP (Good Machine Learning Practice) principles and ISO 13485 quality management systems. Getting this right early, with their guidance, prevents a mountain of regulatory debt down the road.
For any AI-native company building a SaMD, you absolutely need advisors who get the details of things like algorithmic drift. They should be able to help shape a Predetermined Change Control Plan (PCCP) for the adaptive AI from day one, which can let you iterate the model much faster after you get the initial clearance.
Methodology and Source Note
How did we figure this out? We ran a quantitative, data-driven analysis using public corporate team pages, FDA databases, and PubMed author registries. We mapped the backgrounds of advisors against the FDA clearance timelines for key companies, then cross-referenced that with public corporate filings to see what the stated roles and contributions of these board members were. FDA 510(k) cleared device database This approach gives us a pretty objective way to see the link between a company’s clinical governance and how fast they move through the regulatory process. It’s a solid framework for investors evaluating AI health companies. An AI health company’s clinical advisory board is a core part of its regulatory and commercial strategy. For venture capitalists, a deep dive into a target’s clinical governance is a powerful signal of its potential for quick FDA clearance, strong clinical validation, and, in the end, a successful exit. You’re looking for active researchers with real regulatory experience, not just impressive names on a website.
Frequently Asked Questions
How does the clinical advisory board contribute to regulatory approval and market entry for AI health companies?
A well-constituted and engaged clinical advisory board acts as a critical bridge between AI innovation and established medical practice and regulatory bodies. They provide real-world clinical insights, regulatory foresight, and academic credibility, proactively addressing potential pitfalls in product development, trial design, and regulatory strategy. This engagement can significantly streamline submissions, anticipate FDA queries, and ensure clinical relevance and regulatory compliance, potentially shaving months off clearance timelines.
Beyond impressive CVs, what specific attributes or activities of a clinical advisory board should we prioritize during due diligence?
Beyond impressive CVs, prioritize boards that demonstrate active involvement in product development, trial design, and regulatory strategy. Look for advisors who are conduits for real-world clinical insights and regulatory foresight. Their ability to proactively address potential pitfalls and their experience with FDA advisory panels are key indicators of a board’s strategic value in de-risking the path to market and securing commercial success.
Can you provide examples of how strong clinical advisory boards have positively impacted AI health companies’ regulatory and commercial success?
Tempus AI’s formidable clinical advisory network, comprising diverse specialists, is deeply integrated into its oncology validation efforts, correlating with an extensive publication history and facilitating access to high-quality clinical datasets. Cleerly, with its focused advisory board of cardiologists, guides imaging clinical trials and product development, resulting in numerous peer-reviewed publications demonstrating clinical utility. Both companies have achieved significant regulatory clearances and commercial milestones, illustrating the impact of robust clinical governance.
